Vadim S Koshkin
Overview
Explore the profile of Vadim S Koshkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zarrabi K, Saxena A, Mouw K, Koshkin V, Friedlander T
Am Soc Clin Oncol Educ Book
. 2025 Feb;
45(2):e471924.
PMID: 39913872
Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC). In recent years,...
2.
Talukder R, Bakaloudi D, Makrakis D, Diamantopoulos L, Enright T, Leary J, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(1):102284.
PMID: 39798390
Background: FGFR2/3, MTAP and ERBB2 genomic alterations have treatment targets in advanced urothelial carcinoma (aUC). These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC....
3.
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39709257
Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in...
4.
Koshkin V, Danchaivijitr P, Bae W, Semenov A, Ozyilkan O, Su Y, et al.
Eur Urol
. 2024 Dec;
PMID: 39709248
Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreatment. This post hoc analysis evaluated pembrolizumab retreatment in patients...
5.
6.
Kwon D, Trihy L, Darvish N, Hearst E, Sumra S, Borno H, et al.
Cancer Med
. 2024 Nov;
13(22):e70433.
PMID: 39569542
Introduction: Consultation audio recordings improve patient decision-making but are underutilized. Patient-administered recording apps on mobile devices may increase access, but implementation has not been evaluated. Methods: We conducted a single-arm...
7.
Siefker-Radtke A, Huddart R, Bilen M, Balar A, Castellano D, Sridhar S, et al.
Urol Oncol
. 2024 Oct;
PMID: 39477771
Background: In PIVOT-02, bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab (NIVO), a Programmed cell death protein 1 inhibitor, demonstrated the potential to provide additional benefits over...
8.
Bakaloudi D, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary J, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102198.
PMID: 39241315
Background: Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) are associated with immune checkpoint inhibitor (ICI) efficacy. We examined the association between TMB and MSI status with survival in patients...
9.
Graham L, Henderson N, Kellezi O, Hwang C, Barata P, Bilen M, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400014.
PMID: 39178368
Purpose: Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non- homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in men with...
10.
Morris M, de Bono J, Nagarajah J, Sartor O, Wei X, Nordquist L, et al.
Cancer
. 2024 Jul;
130(20):3426-3435.
PMID: 39031642
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) plus protocol-permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression-free survival (rPFS) versus SOC in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate...